Population explosion, availability of life saving drugs and perusal of healthier life styles is leading to rising life expectancy worldwide. This indirectly translates to increasing prevalence of open angle glaucoma worldwide and Pakistan is no exception to these myriad factors of population increase and related healthcare issues.

Studies have in general shown increased glaucoma severity correlating with direct and indirect costs associated with the progression of disease. Hence there is a wide spread tendency to treat suspicious optic nerve heads, mild to moderate high intraocular pressures or even documented but non progressive glaucoma damage without comprehensive structural, visual function, local and systemic risk assessment. This has in turn led to plethora of adverse clinical, socioeconomic and financial concerns triggering chain of adversities at individual and as well as national level.

The term, “target IOP” is widely used in clinical practice. Unfortunately, it tends to steer the management of glaucoma patients solely dependant on reducing IOP to “acceptable” levels. The acceptable target range(s) for IOP are often the recommendations of large land mark clinical trials (RCT’s). This however frequently leads clinicians to ignore the wood for the trees. There is an inclination towards treating the pressure rather than the patient. There is an inclination towards treating the IOP to reduce it to a magic lower value rather than fully assess the patient/ individualised needs, incorporating a holistic approach based on quality of life and patient choice(s). Clinicians in their busy clinics often forget that patients are not concerned about their IOP values, digits (decibel loss) on visual fields or colours (red disease) on OCT scans. Rather patient is only concerned about two things: (a) Am I going to lose vision? or/and (b) am I going to develop disability?

To answer these questions, clinicians are required to assess the progression of the disease and the likelihood of disability in expected life span.

Assessing progression and then the rate of progression is pivotal in taking decisions regarding glaucoma management, for example, it is hard to justify addition of second line of topical ocular antihypertensive drug to a regimen when patient with intraocular pressures of 26 mm Hg on a single ocular antihypertensive drug has not shown any evidence of structural or functional loss on trend analysis. Similarly, a patient with documented progression on visual fields or OCT may still not require further lowering of IOP if the rate of progression is unlikely to cause or worsen existing disability in the life span of terminally ill patient.

Major risk factors for glaucoma blindness are the severity of disease at presentation and life expectancy. A 60 years old patient with bilateral moderate glaucomatous (structural and visual functional) damage at diagnosis has a greater risk of blindness than an 85 years old with a similar amount of damage. Similarly a young patient with mild bilateral damage is at much larger risk of disability in his life tile than an 80 years old patient with moderate unilateral disease. Thus assessing rate of progression is an integral part of glaucoma management and the measured rate is what should determine the target intraocular pressure and treatment intensity. Many
studies have found that progression is usually linear but largely variable (although variable or non-linear progression modelling has been documented as well). Hence the goal of initiating or intensifying the treatment is to reduce the rate of progression to prevent disability or cause further disability. Preservation of visual function and related quality of life should be planned at a sustainable cost. The cost of treatment should be calculated in terms of inconvenience and side effects as well as financial implications for the individual and society and this requires careful evaluation marrying the ‘art and science of glaucoma’.

European Glaucoma Society (EGS) guidelines state, “Quality of life is closely related to visual function. Over all, patients with early to moderate glaucoma damage have good visual function and modest reduction in quality of life (QoL), while QoL is considerably reduced with advanced visual functional loss”8. Common perception that no symptoms are experienced in the early stage of the disease typically9,10 has been challenged in the recent studies, including one large scale epidemiological study. It has been suggested that patients with even mild unilateral visual field damage may experience reduced vision related QoL (VRQoL) even if they are unaware that they suffer from glaucoma11. For example, inferior hemifield damage shows a stronger correlation than superior damage with respect to general vision, risk of falling, eye hand coordination and mobility. While superior field is more likely to interfere with reading and near activities12,13. This decreased quality of life may also result in less engagement in the real world behaviour; significantly reduced physical activity9, restriction to home and suffering with apprehension14 and depression.

Thus when taking in consideration the rate of progression, life expectancy, local and systemic risk factors, patient preferences and effects on vision related quality of Life, it is clear that there is no single “Target IOP” level that is appropriate for every patient. The target IOP needs to be estimated separately for each eye of every patient on every visit.

The Hippocratic Oath includes the promise “Primum non nocere” i.e. as to the matter of diseases, first do no harm. Glaucoma management is complex and requires a holistic approach without bringing harm to patients by carefully identifying “Target IOP”.

**Author’s Affiliation**

Rashid Zia  
Lead Ophthalmologist New Hayesbank Ophthalmology services; Ashford Kent; UK  
Lead Ophthalmologist Beltinge Ophthalmic Services; Kent UK  
Glaucoma Fellow East Kent HospitalsUniversityNHS Foundation Trust UK

Mohammad S. A. Raja  
Consultant Ophthalmologist with a specialist interest in Retinal diseases and Ophthalmic imaging  
Clinical Lead Ophthalmology James Paget University Hospital NHS Trust Norfolk UK  
Clinical Lead EADESP (East Anglian Diabetic Eye Screening Programme)

S. Aqil  
Post graduate trainee

**Financial Interest:** None.

**Conflict of Interest:** None.

**REFERENCES**
8. Terminology and Guidelines for Glaucoma; European Glaucoma Society; 4th Edition; Chapter 3 Treatment Principles and Options, pg 133.


